Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Clinicogenomic characterization of inflammatory breast cancer.

Autor: Priedigkeit N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Harrison B; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Shue R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Hughes M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Li Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Kirkner GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Spurr LF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Remolano MC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Strauss S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Files J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Feeney AM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Grant L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Mohammed-Abreu A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Garrido-Castro A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Sousa RB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bychkovsky B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA., Nakhlis F; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Bellon JR; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA., King TA; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Winer EP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Lindeman N; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Johnson BE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Sholl L; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Dillon D; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Overmoyer B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Cherniack A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Lynce F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 May 10. Date of Electronic Publication: 2024 May 10.